ProKidney Corp (PROK)

Currency in USD
2.530
-0.040(-1.56%)
Closed·
2.510-0.020(-0.79%)
·
PROK is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.4702.560
52 wk Range
0.4607.130
Key Statistics
Prev. Close
2.57
Open
2.56
Day's Range
2.47-2.56
52 wk Range
0.46-7.13
Volume
693.12K
Average Volume (3m)
1.68M
1-Year Change
40.56%
Book Value / Share
-7.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PROK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.500
Upside
+156.92%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

ProKidney Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

ProKidney Corp Company Profile

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Compare PROK to Peers and Sector

Metrics to compare
PROK
Peers
Sector
Relationship
P/E Ratio
−5.0x−2.3x−0.6x
PEG Ratio
−1.66−0.090.00
Price/Book
−0.4x4.4x2.6x
Price / LTM Sales
481.3x10.3x3.2x
Upside (Analyst Target)
156.9%23.7%42.3%
Fair Value Upside
Unlock4.2%5.7%Unlock

Analyst Ratings

4 Buy
3 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.500
(+156.92% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy12.00+374.31%-New CoverageDec 16, 2025
Citi
Buy10.00+295.26%9.00MaintainAug 13, 2025
UBS
Buy8.00+216.21%4.00MaintainJul 15, 2025
Guggenheim
Buy7.00+176.68%6.00MaintainJul 14, 2025
BofA Securities
Sell1.00-60.47%-MaintainJul 09, 2025

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-0.12 / -0.1461
Revenue / Forecast
217.00K / --
EPS Revisions
Last 90 days

PROK Income Statement

People Also Watch

250.05
SNDK
-0.01%
8.480
ONDS
-7.12%
67.50
FISV
-0.66%
197.99
ORCL
+0.25%

FAQ

What Is the ProKidney (PROK) Premarket Price Today?

The ProKidney (PROK) premarket price is 2.523. Premarket price change units: -0.047. Premarket percentage change: -1.830%. Premarket volume: 1,400.000. Current date: 27 Dec 2025. Previous close: 2.570

What Stock Exchange Does ProKidney Trade On?

ProKidney is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ProKidney?

The stock symbol for ProKidney is "PROK."

What Is the ProKidney (PROK) Afterhours Price Today? (Afterhours variable test: 2.510) Current Date: 27 Dec 2025

After hours price: 2.510. After hours price change (units): -0.020. Price change percentage: -0.790%

What Is the ProKidney Market Cap?

As of today, ProKidney market cap is 358.11M.

What Is ProKidney's Earnings Per Share (TTM)?

The ProKidney EPS (TTM) is -0.54.

When Is the Next ProKidney Earnings Date?

ProKidney will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is PROK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ProKidney Stock Split?

ProKidney has split 0 times.

How Many Employees Does ProKidney Have?

ProKidney has 204 employees.

What is the current trading status of ProKidney (PROK)?

As of 27 Dec 2025, ProKidney (PROK) is trading at a price of 2.530, with a previous close of 2.570. The stock has fluctuated within a day range of 2.470 to 2.560, while its 52-week range spans from 0.460 to 7.130.

What Is ProKidney (PROK) Price Target According to Analysts?

The average 12-month price target for ProKidney is USD6.5, with a high estimate of USD12 and a low estimate of USD1. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +156.92% Upside potential.

What Is the PROK Premarket Price?

PROK's last pre-market stock price is 2.523. The pre-market share volume is 1,400.000, and the stock has decreased by -0.047, or -1.830%.

What Is the PROK After Hours Price?

PROK's last after hours stock price is 2.510, the stock has decreased by -0.020, or -0.790%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.